Health care shares are higher, while Merck & Co. (MRK) gets a new drug application for SAFLUTAN (tafluprost) accepted for review by the Food and Drug Administration. According to the company, it submitted an NDA to support the proposed use of SAFLUTAN for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Meanwhile, a Johnson & Johnson (JNJ) unit is recalling hundreds of thousands of potentially leaky insulin pump cartridges that could cause serious health problems, Reuters reports.
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...